Profile of BYON4228, a Selective Pan-Allelic SIRPα Blocking Antibody Designed to Improve Efficacy of Therapeutic Anti-Tumor Antibodies
Time: 12:00 pm
day: Day Two Track A AM
Details:
• BYON4228 potentiates both macrophage- and neutrophil-mediated elimination of hematologic and
solid cancer cells in vitro in the presence of several different tumor-targeting antibodies.
• BYON4228 does not recognize the closely related T-cell expressed SIRPα.
• BYON4228 is well tolerated by cynomolgus monkeys. Clinical studies are planned to start in 2022
